Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ≥ 18 and ≤ 65 years of age~* Documented decreased LAL activity~* Evidence of liver involvement~Exclusion Criteria:~* Clinically significant concurrent disease, serious inter-current illness, concomitant medications or other extenuating circumstances~* Clinically significant abnormal values on laboratory screening tests, other than liver function or lipid panel tests~* Aspartate aminotransferase and/or alanine aminotransferase persistently elevated \> 3x upper limit of normal at screening~* Previous hemopoietic bone marrow or liver transplant~* Current history of alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sebelipase alfa 0.35 mg/kg (Type: EXPERIMENTAL): Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
- Sebelipase alfa 1 mg/kg (Type: EXPERIMENTAL): Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
- Sebelipase alfa 3 mg/kg (Type: EXPERIMENTAL): Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.

Based on this trial design, predict the completion outcome and termination type (if applicable).